---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-084175"
form_type: "8-K"
ticker: "NEUP"
cik: "0001191070"
company_name: "Neuphoria Therapeutics Inc."
filed_at: "2024-10-02T23:59:59+00:00"
generated_at: "2026-05-30T22:07:22.579847+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bionomics to re-domicile from Australia to US via scheme of arrangement with Neuphoria

## Summary
- Holders receive 1 Neuphoria share per 1,440 ordinary shares or per 8 ADSs; estimated post-domicile Nasdaq price ~$3.50.
- Board unanimously recommends approval; shareholder vote expected late Nov 2024, implementation early Dec 2024.
- Re-domicile driven by loss of foreign private issuer status, reduced compliance costs, and greater US investor access.
- No material change to assets, management, operations, or strategy expected; structure designed to be tax-neutral.

## SEC filing metadata
- accession: 0001213900-24-084175
- form_type: 8-K
- ticker: NEUP
- cik: 0001191070
- company_name: Neuphoria Therapeutics Inc.
- filed_at: 2024-10-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1191070/000121390024084175/0001213900-24-084175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1191070/000121390024084175/ea0216237-8k_bionomic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-084175
- JSON: https://secwatch.observer/filing/0001213900-24-084175.json
- Plain text: https://secwatch.observer/filing/0001213900-24-084175.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.